Holen Sie sich die Stockscreener-App
0.9547
0.97%
0.0092
Handel nachbörslich:
.95
-0.0047
-0.49%
Schlusskurs vom Vortag:
$0.9455
Offen:
$0.95
24-Stunden-Volumen:
167.03K
Relative Volume:
1.42
Marktkapitalisierung:
$18.67M
Einnahmen:
$411.00K
Nettoeinkommen (Verlust:
$-4.85M
KGV:
-2.1698
EPS:
-0.44
Netto-Cashflow:
$-4.88M
1W Leistung:
+14.46%
1M Leistung:
-0.55%
6M Leistung:
-50.79%
1J Leistung:
-65.03%
1-Tages-Spanne:
$0.925
$0.98
1-Wochen-Bereich:
$0.7941
$0.98
52-Wochen-Spanne:
$0.7941
$4.38
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Firmenname
Lexaria Bioscience Corp
Sektor
Branche
Telefon
250-765-6424
Adresse
100 - 740 MCCURDY ROAD, KELOWNA
Vergleichen Sie LEXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.9547 | 16.31M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Is Lexaria Bioscience Corp. Equity Warrant a good long term investmentFree Predictions - Autocar Professional
What drives Lexaria Bioscience Corp. Equity Warrant stock priceFree Trading Strategy Suggestions - Autocar Professional
What analysts say about Lexaria Bioscience Corp. Equity Warrant stockSuperior trading gains - PrintWeekIndia
Lexaria Bioscience Corp. Equity Warrant Stock Analysis and ForecastTriple-digit return opportunities - Autocar Professional
What drives Lexaria Bioscience Corp. stock priceSuperior stock growth - Autocar Professional
What analysts say about Lexaria Bioscience Corp. stockHigh-yield growth strategies - jammulinksnews.com
Is Lexaria Bioscience Corp. a good long term investmentConsistently superior profits - jammulinksnews.com
How high can Lexaria Bioscience Corp. stock price go in 2025Short Squeeze Radar - Newser
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule - MSN
Lexaria Bioscience stock hits 52-week low at $1.62 - MSN
Lexaria Bioscience Third Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Why Lexaria Bioscience Corp. stock attracts strong analyst attentionSafer Investing With Bigger Upside - Newser
How Lexaria Bioscience Corp. stock performs during market volatilityMassive Upside Selection - Newser
What makes Lexaria Bioscience Corp. Equity Warrant stock price move sharplyFree Stock Market Forums - Newser
Why Lexaria Bioscience Corp. Equity Warrant stock attracts strong analyst attentionLow Risk Entry Points - Newser
What makes Lexaria Bioscience Corp. stock price move sharplyFree Smart Money Group - Newser
How Lexaria Bioscience Corp. Equity Warrant stock performs during market volatilityPro Trader Stock Focus - Newser
Lexaria Bioscience 2025 Q3 Earnings Misses Targets as Net Loss Widens 112% - AInvest
Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2025 - MarketScreener
Lexaria Bioscience Corp. SEC 10-Q Report - TradingView
Contrasting Lexaria Bioscience (OTCMKTS:LXRP) & Anglo American (OTCMKTS:NGLOY) - Defense World
LEXARIA BIOSCIENCE Earnings Preview: Recent $LEXX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Lexaria Bioscience Corp expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Research Analysts Issue Forecasts for LEXX FY2025 Earnings - Defense World
Research Analysts Issue Forecasts for LEXX Q1 Earnings - Defense World
Lexaria Bioscience stock price target lowered to $5 at H.C. Wainwright - Investing.com
Lexaria Bioscience Achieves 50 Patents Milestone with New International Grants - TipRanks
Lexaria Reaches Patent Milestone50 Patents Now Granted Worldwide - TradingView
LEXX: GLP-1-H25-5 Study Complete - Yahoo Finance
Finanzdaten der Lexaria Bioscience Corp-Aktie (LEXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):